Table 1 Summary of sero-negative, acute, and convalescent-phase of COVID-19 patients from which the plasma ACE2+ EVs and RBD-IgG levels were measured.
From: Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
Sero-negative (N = 5) | CSB convalescent (N = 61) | CBB acute phase cohort (N = 23) | ||||
|---|---|---|---|---|---|---|
Mean/count | SD (%) | Mean/count | SD (%) | Mean/count | SD (%) | |
Age, years | 39.7 | 15.9 | 42.9 | 15.0 | 61.5 | 15.4 |
Sex, male | 0 | 0.0% | 23 | 36.9% | 13 | 56.5% |
Race | ||||||
Black | 0 | 0.0% | 6 | 9.4% | 9 | 39.1% |
White | 3 | 60.0% | 37 | 57.8% | 9 | 39.1% |
Asian | 0 | 0.0% | 4 | 6.3% | 1 | 4.4% |
Other | 2 | 40.0% | 17 | 26.6% | 4 | 17.4% |
SOFA scorea | NA (N = 0) | NA | 6.0 (N = 4) | 3.4 | 8.6 (N = 14) | 4.1 |
Intermediate to advanced interventions | ||||||
Vasopressor use | 0 | 0.0% | 4 | 6.3% | 10 | 43.5% |
High flow nasal cannula | 0 | 0.0% | 2 | 3.1% | 12 | 52.2% |
Non-invasive ventilation | 0 | 0.0% | 1 | 1.6% | 3 | 13.0% |
Mechanical ventilation | 0 | 0.0% | 3 | 4.7% | 13 | 56.5% |
Length of stay (LOS, days) | ||||||
ICU patients | NA (N = 0) | NA | 22.4 (N = 5) | 16.1 | 31.3 (N = 15) | 16.7 |
Inpatients | NA (N = 0) | NA | 5.1 (N = 7) | 3.0 | 9.5 (N = 8) | 5.7 |
Onset to sampling, days | NA | NA | 87.5 | 47.8 | 12.9 | 9.4 |
